Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance
4
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Treatment of intrahepatic cholangiocarcinoma (iCCA) is currently at a significant turning point due to the identification of isocitrate dehydrogenase (IDH) mutations and fibroblast growth factor receptor (FGFR) fusions that can be targeted with currently available therapies. Clinical trials of these targeted therapies have been promising, and the iCCA patients who may benefit from these targeted treatments can be identified by pathological examination prior to molecular investigations. This is because IDH mutations and FGFR fusions are mainly seen in the small duct type iCCA, a subtype of iCCA defined by the 5th World Health Organization classification, which can be recognized by the pathological diagnostic process. Therefore, pathology plays an important role in precision medicine for iCCA, not only in confirming the diagnosis, but also in identifying the iCCA patients who may benefit from targeted treatments. However, caution is advised with the pathological diagnosis, as iCCA shows tumour heterogeneity, making it difficult to distinguish small duct type iCCA from hepatocellular carcinoma (HCC), and combined HCC-CCA. This review focuses on the pathological/ molecular features of both subtypes of iCCA (large and small duct types), as well as their diagnostic pitfalls, clinical relevance, and future perspectives.
Abstract
Treatment of intrahepatic cholangiocarcinoma (iCCA) is currently at a significant turning point due to the identification of isocitrate dehydrogenase (IDH) mutations and fibroblast growth factor receptor (FGFR) fusions that can be targeted with currently available therapies. Clinical trials of these targeted therapies have been promising, and the iCCA patients who may benefit from these targeted treatments can be identified by pathological examination prior to molecular investigations. This is because IDH mutations and FGFR fusions are mainly seen in the small duct type iCCA, a subtype of iCCA defined by the 5th World Health Organization classification, which can be recognized by the pathological diagnostic process. Therefore, pathology plays an important role in precision medicine for iCCA, not only in confirming the diagnosis, but also in identifying the iCCA patients who may benefit from targeted treatments. However, caution is advised with the pathological diagnosis, as iCCA shows tumour heterogeneity, making it difficult to distinguish small duct type iCCA from hepatocellular carcinoma (HCC), and combined HCC-CCA. This review focuses on the pathological/ molecular features of both subtypes of iCCA (large and small duct types), as well as their diagnostic pitfalls, clinical relevance, and future perspectives.
참고문헌 (48)
- Nakanuma Y, "Intrahepatic cholangiocarcinoma", Lyon: IARC (2019)
- Banales JM, "Cholangiocarcinoma 2020 : the next horizon in mechanisms and management", Nat Rev Gastroenterol Hepatol, 17, pp.557~588 (2020)
- Bekaii-Saab TS, "Practical considerations in screening for genetic alterations in cholangiocarcinoma", Ann Oncol, 32, pp.1111~1126 (2021)
- Tsujie M, "Fibroblast growth factor receptor 2(FGFR2)fusions in Japanese patients with intrahepatic cholangiocarcinoma", Jpn J Clin Oncol, 51, pp.911~917 (2021)
- Javle M, "Biliary cancer : utility of next-generation sequencing for clinical management", Cancer, 122, pp.3838~3847 (2016)
- Lowery MA, "Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas : potential targets for intervention", Clin Cancer Res, 24, pp.4154~4161 (2018)
- Abou-Alfa GK, "Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma : a multicentre, openlabel, phase 2 study", Lancet Oncol, 21, pp.671~684 (2020)
- Zhu AX, "Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation : the phase 3 randomized clinical ClarIDHy trial", JAMA Oncol, 7, pp.1669~1677 (2021)
- Javle M, "Infigratinib(BGJ398)in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements : mature results from a multicentre, open-label, single-arm, phase 2 study", Lancet Gastroenterol Hepatol, 6, pp.803~815 (2021)
- Bagante F, "Defining when to offer operative treatment for intrahepatic cholangiocarcinoma : a regret-based decision curves analysis", Surgery, 160, pp.106~117 (2016)
- Farges O, "Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma : a multicenter study by the AFC-IHCC-2009 study group", Ann Surg, 254, pp.824~829 (2011)[DOI]
- Moeckli B, "Recent developments and ongoing trials in transplant oncology", Liver Int, 40, pp.2326~2344 (2020)
- Bertuccio P, "Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma", J Hepatol, 71, pp.104~114 (2019)
- Mina Komuta, "Histological Heterogeneity of Primary Liver Cancers: Clinical Relevance, Diagnostic Pitfalls and the Pathologist’s Role", Cancers, 13(12), pp.2871~ (2021), MDPI AG[DOI]
- Komuta M, "Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes", Hepatology, 55, pp.1876~1888 (2012)
- Kudo M, "Report of the 21st nationwide follow-up survey of primary liver cancer in Japan(2010-2011)", Hepatol Res, 51, pp.355~405 (2021)
- Akita M, "Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas", Mod Pathol, 30, pp.986~997 (2017)
- Hayashi A, "Distinct clinicopathologic and genetic features of 2histologic subtypes of intrahepatic cholangiocarcinoma", Am J Surg Pathol, 40, pp.1021~1030 (2016)
- Liau JY, "Morphological subclassification of intrahepatic cholangiocarcinoma : etiological, clinicopathological, and molecular features", Mod Pathol, 27, pp.1163~1173 (2014)
- Ahn KS, "Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular-clinical analysis and potential targeted approach", Hepatol Int, 13, pp.490~500 (2019)
- Jusakul A, "Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma", Cancer Discov, 7, pp.1116~1135 (2017)
- Boerner T, "Genetic determinants of outcome in intrahepatic cholangiocarcinoma", Hepatology, 74, pp.1429~1444 (2021)
- Sia D, "Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes", Gastroenterology, 144, pp.829~840 (2013)
- Andersen JB, "Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors", Gastroenterology, 142, pp.1021~1031 (2012)
- Israel MA, "Comparative genomic analysis of intrahepatic cholangiocarcinoma : biopsy type, ancestry, and testing patterns", Oncologist, 26, pp.787~796 (2021)
- Farshidfar F, "Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles", Cell Rep, 18, pp.2780~2794 (2017)
- Steiner PE, "Cholangiolocellular carcinoma of the liver", Cancer, 12, pp.753~759 (1959)
- Komuta M, "Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin", Hepatology, 47, pp.1544~1556 (2008)
- Sempoux C, "WHO classification of tumours of the digestive system", pp.260~262 (2019), IARC
- Moeini A, "Mixed hepatocellular cholangiocarcinoma tumors : cholangiolocellular carcinoma is a distinct molecular entity", J Hepatol, 66, pp.952~961 (2017)
- Komuta M, "A Review on the update of combined hepatocellular cholangiocarcinoma", Semin Liver Dis, 40, pp.124~130 (2020)
- Akiba J, "Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification", Am J Surg Pathol, 37, pp.496~505 (2013)
- Park SH, "Combined hepatocellular-cholangiocarcinoma : gadoxetic acid-enhanced MRI findings correlated with pathologic features and prognosis", J Magn Reson Imaging, 46, pp.267~280 (2017)
- Elsayes KM, "LI-RADS : a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance", J Hepatocell Carcinoma, 6, pp.49~69 (2019)
- Choi SH, "Radiopathologic correlation of biphenotypic primary liver cancer(combined hepatocellular cholangiocarcinoma) : changes in the 2019 WHO classification and impact on LI-RADS classification at liver MRI", Eur Radiol, 31, pp.9479~9488 (2021)
- Gigante E, "Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellular-cholangiocarcinoma", Liver Int, 39, pp.2386~2396 (2019)
- Durnez A, "The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin", Histopathology, 49, pp.138~151 (2006)
- Govaere O, "Keratin 19 : a key role player in the invasion of human hepatocellular carcinomas", Gut, 63, pp.674~685 (2014)
- Fong ZV, "The clinical management of cholangiocarcinoma in the United States and Europe : a comprehensive and evidence-based comparison of guidelines", Ann Surg Oncol, 28, pp.2660~2674 (2021)
- Bedossa P, "Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients", Hepatology, 56, pp.1751~1759 (2012)
- De Martin E, "Analysis of liver resection versus liver transplantation on outcome of small intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in the setting of cirrhosis", Liver Transpl, 26, pp.785~798 (2020)
- Sapisochin G, "Liver transplantation for"very early"intrahepatic cholangiocarcinoma : International retrospective study supporting a prospective assessment", Hepatology, 64, pp.1178~1188 (2016)
- Lamarca A, "Advanced intrahepatic cholangiocarcinoma : post hoc analysis of the ABC-01, -02, and-03 clinical trials", J Natl Cancer Inst, 112, pp.200~210 (2020)
- Lee SH, "Genomic profiling of multifocal intrahepatic cholangiocarcinoma reveals intraindividual concordance of genetic alterations", Carcinogenesis, 42, pp.436~441 (2021)
- Lamarca A, "Liver metastases of intrahepatic cholangiocarcinoma : implications for an updated staging system", Hepatology, 73, pp.2311~2325 (2021)
- Gutiérrez-Larrañaga M, "Immune checkpoint inhibitors : the emerging cornerstone in cholangiocarcinoma therapy?", Liver Cancer, 10, pp.545~560 (2021)
- Feng K, "Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers : results from a phase II study", J Immunother Cancer, 8, pp.e000367~ (2020)
- Ueno M, "Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer : a non-randomised, multicentre, open-label, phase 1 study", Lancet Gastroenterol Hepatol, 4, pp.611~621 (2019)